Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative bevacizumab + trastuzumab + weekly paclitaxel followed by postoperative liposomal doxorubicin + cyclophosphamide + trastuzumab in HER2-positive early breast cancer
2009-011405-16Phase 2Completed
- Sponsor
- Fundación de Investigación HM Hospitales
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by Fundación de Investigación HM Hospitales. Primary endpoint: Pathological response rate in breast and axilla. Started Apr 2009; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-011405-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011405-16.